Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Serina Therapeutics, Inc. (SER : AMEX)

• Company Description    Serina Therapeutics Inc. is a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson's Disease and other neurological diseases. Serina Therapeutics Inc., formerly known as AgeX Therapeutics Inc., is based in HUNTSVILLE, Ala. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $5.19 Daily Weekly Monthly 20 Day Moving Average: 337,444 shares Shares Outstanding: 10.25 (millions) Market Capitalization: $53.20 (millions) Beta: 0.76 52 Week High: $10.28 52 Week Low: $3.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.64% -7.30% 12 Week -9.74% -18.01% Year To Date 3.59% -9.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 601 GENOME WAY SUITE 2001 - HUNTSVILLE,AL 35806 USA ph: 256-327-9630 fax: 510-671-8619 None https://serinatherapeutics.com

• General Corporate Information    Officers Steve Ledger - Chief Executive Officer and Director Balkrishan Gill - Executive Chairman of the Board of Directors Gregory S. Curhan - Chief Financial Officer Remy Gross - Director Richard Marshall - Director Peer Information Serina Therapeutics, Inc. (CORR.) Serina Therapeutics, Inc. (RSPI) Serina Therapeutics, Inc. (CGXP) Serina Therapeutics, Inc. (BGEN) Serina Therapeutics, Inc. (GTBP) Serina Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81751A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 10.25 Most Recent Split Date: 3.00 (0.03:1) Beta: 0.76 Market Capitalization: $53.20 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.01 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 16.85 EPS Growth vs. Year Ago Period: -229.41% vs. Previous Quarter: -34.69% Sales Growth vs. Year Ago Period: 154.90% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -168.83 03/31/25 - -11.89 12/31/24 - -62.29 Current Ratio 06/30/25 - 2.24 03/31/25 - 2.45 12/31/24 - 2.40 Quick Ratio 06/30/25 - 2.24 03/31/25 - 2.45 12/31/24 - 2.40 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -9,733.08 03/31/25 - -1,988.23 12/31/24 - -20,012.50 Book Value 06/30/25 - -0.33 03/31/25 - 0.16 12/31/24 - 0.06 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©